デフォルト表紙
市場調査レポート
商品コード
1703488

口腔乾燥症治療薬市場- 世界の産業規模、シェア、動向、機会および予測、タイプ別（OTC、処方）、製品別（唾液分泌促進剤、唾液代用品、歯磨剤）、地域別および競合別セグメント、2020-2030年

Xerostomia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type (OTC, Prescription), By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices), By Region & Competition, 2020-2030F

出版日
ページ情報
英文 180 Pages
納期
2～3営業日
カスタマイズ可能
口腔乾燥症治療薬市場- 世界の産業規模、シェア、動向、機会および予測、タイプ別（OTC、処方）、製品別（唾液分泌促進剤、唾液代用品、歯磨剤）、地域別および競合別セグメント、2020-2030年
出版日: 2025年04月11日
発行: TechSci Research
ページ情報: 英文 180 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

口腔乾燥症治療薬の世界市場規模は2024年に21億5,000万米ドルとなり、2030年までの年間平均成長率（CAGR）は3.75％と、着実な成長が見込まれています。

この市場には、口腔乾燥症（一般にドライマウスと呼ばれる）の症状を管理・緩和することを目的としたさまざまな製品や治療が含まれます。

市場概要
予測期間 2026-2030
市場規模：2024年 21億5,000万米ドル
市場規模：2030年 26億9,000万米ドル
CAGR：2025年～2030年 3.75%
急成長セグメント OTC
最大市場 北米

口腔乾燥症は、唾液腺機能の低下または欠如を特徴とする病態であり、唾液分泌量の減少をもたらします。薬剤の副作用、慢性疾患、放射線療法、自然な老化プロセスなど、さまざまな要因によって引き起こされます。

主な市場促進要因

高齢化人口の増加

主な市場課題

認知度の低下と過小診断

主要市場動向

個別化医療と標的治療アプローチ

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 口腔乾燥症治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 種類別（市販薬、処方薬）
    • 製品別（唾液分泌促進剤、唾液代替物、歯磨き剤）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米の口腔乾燥症治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の口腔乾燥症治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋地域の口腔乾燥症治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の口腔乾燥症治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの口腔乾燥症治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 世界の口腔乾燥症治療薬市場：SWOT分析

第14章 競合情勢

  • GlaxoSmithKline plc
  • Church & Dwight Co., Inc.
  • Colgate-Palmolive Company
  • Hikma Pharmaceuticals PLC
  • Pendopharm
  • Sun Pharmaceuticals Industries Ltd
  • Lupin Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Parnell Pharmaceuticals, Inc.
  • Acacia Pharma.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 16619

Global Xerostomia Therapeutics Market was valued at USD 2.15 billion in 2024 and is expected to register steady growth, projecting a compound annual growth rate (CAGR) of 3.75% through 2030. This market encompasses a range of products and treatments aimed at managing and alleviating the symptoms of xerostomia-commonly referred to as dry mouth.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.15 Billion
Market Size 2030USD 2.69 Billion
CAGR 2025-20303.75%
Fastest Growing SegmentOTC
Largest MarketNorth America

Xerostomia is a condition characterized by diminished or absent salivary gland function, resulting in reduced saliva production. It can be caused by a variety of factors, including side effects of medications, chronic illnesses, radiation therapy, and the natural aging process.

Key Market Drivers

Growing Aging Population

The increasing global aging population is a primary driver for the expansion of the xerostomia therapeutics market. By 2050, approximately 80% of the world's elderly population is projected to reside in low- and middle-income countries-marking a substantial demographic shift with far-reaching economic and healthcare implications.

The pace of population aging is accelerating, creating both challenges and new opportunities within the healthcare sector. Notably, in 2020, the global population aged 60 and above exceeded the number of children under the age of five for the first time. Between 2015 and 2050, the proportion of individuals aged 60+ is expected to nearly double from 12% to 22%, emphasizing the urgent need for age-responsive healthcare solutions and infrastructure.

Xerostomia is particularly prevalent among older adults due to age-related decline in salivary gland function, which reduces saliva production. This not only impacts seniors' comfort and quality of life but also increases their susceptibility to oral infections and dental problems. Consequently, the elderly represent a growing and high-priority target group for xerostomia therapeutics.

Prevalence estimates for xerostomia in the general population vary widely, ranging from 0.9% to 64.8%, but the condition is significantly more common among older individuals-affecting approximately 30% of those over 65 and up to 40% of those over 80. In addition, seniors are more likely to be prescribed multiple medications for chronic conditions such as hypertension, diabetes, and cardiovascular disease, many of which list dry mouth as a common side effect. This further increases the incidence of xerostomia in older adults and, in turn, drives demand for effective treatment options to alleviate symptoms and improve adherence to long-term medication regimens.

Key Market Challenges

Limited Awareness and Underdiagnosis

One of the primary challenges facing the xerostomia therapeutics market is the widespread underdiagnosis of the condition. Because dry mouth often appears as a secondary symptom of other diseases or medication use, it is frequently overlooked in clinical settings.

Healthcare professionals may not always recognize xerostomia as a standalone issue, which can delay diagnosis and treatment. Additionally, many individuals experiencing dry mouth are unaware that the condition is medically treatable. Symptoms are often mistaken as normal aspects of aging or expected medication side effects, leading patients to forgo medical consultation. This lack of awareness-both among healthcare providers and the general public-poses a barrier to market growth.

Key Market Trends

Personalized Medicine and Targeted Therapeutic Approaches

A notable trend within the xerostomia therapeutics market is the shift toward personalized medicine. Advances in genomics and molecular science are providing deeper insights into the genetic and biological mechanisms that contribute to xerostomia in individual patients, enabling the development of more precise and effective treatments.

Pharmacogenomics-the study of how genetic variations influence drug response-is becoming increasingly important in tailoring xerostomia therapies. This approach allows clinicians to identify the most suitable treatment options for individual patients, thereby minimizing ineffective treatments and improving outcomes.

Ongoing research is also focused on identifying biomarkers associated with xerostomia, which may facilitate early diagnosis and aid in the selection of optimal treatment strategies. These developments hold significant promise for enhancing therapeutic efficacy and offering more targeted, personalized care to patients suffering from dry mouth.

Key Market Players

  • GlaxoSmithKline plc
  • Church & Dwight Co., Inc.
  • Colgate-Palmolive Company
  • Hikma Pharmaceuticals PLC
  • Pendopharm
  • Sun Pharmaceuticals Industries Ltd
  • Lupin Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Parnell Pharmaceuticals, Inc.
  • Acacia Pharma

Report Scope:

In this report, the Global Xerostomia Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Xerostomia Therapeutics Market, By Type:

  • OTC
  • Prescription

Xerostomia Therapeutics Market, By Product:

  • Salivary Stimulants
  • Salivary Substitutes
  • Dentifrices

Xerostomia Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Xerostomia Therapeutics Market.

Available Customizations:

Global Xerostomia Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Xerostomia Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (OTC, Prescription)
    • 5.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Xerostomia Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Product
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Xerostomia Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Product
    • 6.3.2. Canada Xerostomia Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Product
    • 6.3.3. Mexico Xerostomia Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Product

7. Europe Xerostomia Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Product
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Xerostomia Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Product
    • 7.3.2. United Kingdom Xerostomia Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Product
    • 7.3.3. Italy Xerostomia Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Product
    • 7.3.4. France Xerostomia Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Product
    • 7.3.5. Spain Xerostomia Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Product

8. Asia-Pacific Xerostomia Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Product
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Xerostomia Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Product
    • 8.3.2. India Xerostomia Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Product
    • 8.3.3. Japan Xerostomia Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Product
    • 8.3.4. South Korea Xerostomia Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Product
    • 8.3.5. Australia Xerostomia Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Product

9. South America Xerostomia Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Product
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Xerostomia Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Product
    • 9.3.2. Argentina Xerostomia Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Product
    • 9.3.3. Colombia Xerostomia Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Product

10. Middle East and Africa Xerostomia Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Product
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Xerostomia Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product
    • 10.3.2. Saudi Arabia Xerostomia Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product
    • 10.3.3. UAE Xerostomia Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Xerostomia Therapeutics Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. GlaxoSmithKline plc
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Church & Dwight Co., Inc.
  • 14.3. Colgate-Palmolive Company
  • 14.4. Hikma Pharmaceuticals PLC
  • 14.5. Pendopharm
  • 14.6. Sun Pharmaceuticals Industries Ltd
  • 14.7. Lupin Pharmaceuticals, Inc.
  • 14.8. Pfizer, Inc.
  • 14.9. Parnell Pharmaceuticals, Inc.
  • 14.10.Acacia Pharma.

15. Strategic Recommendations

16. About Us & Disclaimer